UroGen Pharma (URGN) EBT: 2016-2025
Historic EBT for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$34.4 million.
- UroGen Pharma's EBT fell 45.88% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.6 million, marking a year-over-year decrease of 45.18%. This contributed to the annual value of -$124.0 million for FY2024, which is 26.16% down from last year.
- Per UroGen Pharma's latest filing, its EBT stood at -$34.4 million for Q3 2025, which was up 29.69% from -$48.9 million recorded in Q2 2025.
- UroGen Pharma's 5-year EBT high stood at -$21.9 million for Q3 2023, and its period low was -$48.9 million during Q2 2025.
- Over the past 3 years, UroGen Pharma's median EBT value was -$32.2 million (recorded in 2024), while the average stood at -$31.7 million.
- Per our database at Business Quant, UroGen Pharma's EBT soared by 31.44% in 2021 and then slumped by 57.31% in 2024.
- Quarterly analysis of 5 years shows UroGen Pharma's EBT stood at -$27.3 million in 2021, then decreased by 3.17% to -$28.2 million in 2022, then increased by 21.36% to -$22.2 million in 2023, then slumped by 57.31% to -$34.9 million in 2024, then tumbled by 45.88% to -$34.4 million in 2025.
- Its last three reported values are -$34.4 million in Q3 2025, -$48.9 million for Q2 2025, and -$43.5 million during Q1 2025.